Keywords
tumor
DISEASE, TUMOR, COLORECTAL CANCER, POSTOPERATIVE COMPLICATIONS
Open access funding provided by Università degli Studi di Torino within the CRUI-CARE Agreement.Colorectal cancer (CC) is the third most common tumor worldwide and ranks second in terms of death-related cancer/year. Actually, the standard of care is surgery, with 5-year survival rates of 80% or higher for all stages together, excluding stage IV disease.In 1907 HalstedSeveral authors have reported main differences between right- and left-sided CC in terms of molecular alterations, treatment responsiveness, and survival rates.In 2009, Hohenberger et al.This new technique suddenly raised a great interest among surgeons, who attempted to demonstrate its superiority over the standard right colectomy. Nevertheless, to date there aren’t enough data supporting its routine adoption for RSCC treatment, in terms of both the number of LNs yielded and the survival rates.Very recently two randomized controlled trials (RCT) comparing CME with standard right colectomy have been published. The RELARC study is a multicenter, high-volume, phase 3 superiority trial from China, whereas the Agrusa study is a single-center low-volume trial from Italy.Our multicenter trial with a large Western population aims to investigate the three main outcomes of a controlled CME: the quality of surgery (number of nodes retrieved, integrity and area of resected mesocolon, length of IC and MC vessels, and Benz classification), its safety (intra- and postoperative complications), and its efficacy (early oncologic items and survival rates).